Sotrovimab Monoclonal Antibody Treatment Effective at Reducing Severe Disease from Omicron COVID-19 Variant

Growing evidence over the past weeks has shown that sotrovimab is the most effective monoclonal antibody treatment against the Omicron variant of COVID-19 for people who are at high risk of severe disease.

Individuals who are eligible and would like to receive a monoclonal antibody treatment (see eligibility requirements below) should call our Monoclonal Antibody Infusion Center to be screened for an appointment. Treatments are provided in an outpatient setting and may take up to three hours to complete.

Monoclonal Antibody Infusion Center: 909.282.3256

*Appointments are required.

What is monoclonal antibody treatment/sotrovimab?

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses. Monoclonal antibodies are administered intravenously and used to treat mild-to-moderate symptoms of COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing, and who are at high risk of progression to severe COVID-19, including hospitalization or death.

Sotrovimab is a monoclonal antibody that is specifically directed against the spike protein of SARS-CoV-2 and is designed to block the virus’ attachment and entry into human cells. Sotromivab was originally issued an emergency use authorization (EUA) by the U.S Food and Drug Administration (FDA) in May of 2021. Learn more about sotrovimab here.

Who is eligible to receive monoclonal antibody treatment?

Monoclonal antibody treatment is for non-hospitalized patients who have been newly diagnosed with COVID-19.

Sotromivab should be administered as soon as possible after a positive viral test for COVID-19 and within 10 days of symptom onset in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death.

The following medical conditions or other factors may place patients at higher risk for progression to severe COVID-19:

• Immunocompromised individuals regardless of age and vaccine status.
• Age 65 and older especially if unvaccinated.
• Obesity or being overweight (for example, adults with BMI >30 kg/m2 , or if 12 to 17, have BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm)
• Chronic kidney disease
• Diabetes
• Chronic lung diseases, and Cardiovascular disease
• Pregnancy
• HIV/AIDS
• Sickle cell disease
• Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)

Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19. Learn more on the CDC website.